SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Guj. Themis Biosyn - Quaterly Results

26 Jul 2024 Evaluate
The sales is pegged at Rs. 388.27 millions for the June 2024 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 495.88 millions during the year-ago period.The Company's Net profit for the June 2024 quarter have declined marginally to Rs. 132.37  millions as against Rs. 177.21 millions reported during the corresponding quarter ended.The Operating Profit of the company witnessed a decrease to 190.75 millions from 245.81 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 388.27 495.88 -21.70 388.27 495.88 -21.70 1698.22 1483.85 14.45
Other Income 5.24 10.75 -51.26 5.24 10.75 -51.26 43.66 65.88 -33.73
PBIDT 190.75 245.81 -22.40 190.75 245.81 -22.40 831.00 802.17 3.59
Interest 0.66 0.25 164.00 0.66 0.25 164.00 2.29 1.76 30.11
PBDT 190.09 245.56 -22.59 190.09 245.56 -22.59 828.71 800.41 3.54
Depreciation 11.48 7.49 53.27 11.48 7.49 53.27 35.36 25.76 37.27
PBT 178.61 238.07 -24.98 178.61 238.07 -24.98 793.35 774.65 2.41
TAX 46.24 60.86 -24.02 46.24 60.86 -24.02 201.71 194.96 3.46
Deferred Tax 0.53 0.96 -44.79 0.53 0.96 -44.79 3.75 2.55 47.06
PAT 132.37 177.21 -25.30 132.37 177.21 -25.30 591.64 579.69 2.06
Equity 72.64 72.64 0.00 72.64 72.64 0.00 72.64 72.64 0.00
PBIDTM(%) 49.13 49.57 -0.89 49.13 49.57 -0.89 48.93 54.06 -9.48

Guj. Themis Biosyn Share Price

319.45 15.45 (5.08%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×